Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label community study of Zepatier (elbasvir + grazoprevir ± ribavirin) in HCV genotype 1/4 patients on opiate substitution therapy
2016-003414-26Phase 4Terminated
- Sponsor
- Dr. John Lambert (Mater Misericordiae University Hospital)
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of grazoprevir in hepatitis C virus infection (2 arms), sponsored by Dr. John Lambert (Mater Misericordiae University Hospital). Primary endpoint: SVR12. Started Sep 2017; status: terminated.
02
Drugs
grazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2016-003414-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003414-26.